Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Grazyna Lipowska-Bhalla, Ester Fagnano, Timothy M. Illidge & Eleanor J. Cheadle. (2016) Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leukemia & Lymphoma 57:6, pages 1269-1280.
Read now
Read now
Luis Fayad, Stephen M. Ansell, Ranjana Advani, Bertrand Coiffier, Robert Stuart, Nancy L. Bartlett, Andres Forero-Torres, Kazimierz Kuliczkowski, David Belada, Edmund Ng & Jonathan G. Drachman. (2015) Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia & Lymphoma 56:9, pages 2569-2578.
Read now
Read now
Mohamed A Hussein. (2005) Multiple myeloma: an update of developments in targeted therapy. Expert Review of Anticancer Therapy 5:2, pages 379-389.
Read now
Read now
Valter Gattei, Massimo Degan, Francesca Maria Rossi, Angela De Iuliis, Francesca Tassan Mazzocco, Diego Serramo, Vittorlna Zagonel, Donatella Aldinucci & Antonio Pinto. (1999) CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation. Leukemia & Lymphoma 35:1-2, pages 21-35.
Read now
Read now
Articles from other publishers (29)
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Thomas F Gajewski, Martin Gutierrez, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Elisabeth I Heath, John A Thompson, Sahar Ansari, Celine Jacquemont, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt & Juneko E Grilley-Olson. (2023) Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. Journal for ImmunoTherapy of Cancer 11:6, pages e005584.
Crossref
Crossref
Veysel GÖK, Alper ÖZCAN, Ebru YILMAZ, Musa KARAKÜKCÜ, Türkan PATIROĞLU, Mehmet Akif ÖZDEMİR & Ekrem ÜNAL. (2022) The Significance of soluble CD40 and CD40 ligand levels in childhood acute lymphoblastic leukemia patients. Journal of Translational and Practical Medicine 1:2.
Crossref
Crossref
Li Wang, Wei Qin, Yu-Jia Huo, Xiao Li, Qing Shi, John E. J. Rasko, Anne Janin & Wei-Li Zhao. (2020) Advances in targeted therapy for malignant lymphoma. Signal Transduction and Targeted Therapy 5:1.
Crossref
Crossref
Adam Jona, Peter Szodoray & Arpad Illés. (2013) Immunologic pathomechanism of Hodgkin's lymphoma. Experimental Hematology 41:12, pages 995-1004.
Crossref
Crossref
Eun Kyung Lee, Ji Hye Chae & Myung-Soo Kang. (2011) Nuclear factor-κB2 represses Sp1-mediated transcription at the CD99 promoter. Molecules and Cells 32:6, pages 555-560.
Crossref
Crossref
Lyudmyla Derby & Myron S Czuczman. (2011) Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncology 7:8, pages 963-979.
Crossref
Crossref
Roch Houot, Holbrook Kohrt, Matthew J. Goldstein & Ronald Levy. (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer and Metastasis Reviews 30:1, pages 97-109.
Crossref
Crossref
Annette Hollmann, Raquel Aloyz, Kristi Baker, Stephan Dirnhofer, Trevor Owens, Robert Sladek & Alexandar Tzankov. (2010) Vav‐1 expression correlates with NFκB activation and CD40‐mediated cell death in diffuse large B‐cell lymphoma cell lines. Hematological Oncology 28:3, pages 142-150.
Crossref
Crossref
Elizabeth J. Soilleux. (2010) Recent advances in mastocytosis and neoplasms of probable monocytic/dendritic cell lineage. Diagnostic Histopathology 16:4, pages 182-205.
Crossref
Crossref
Ranjana AdvaniAndres Forero-TorresRichard R. FurmanJoseph D. RosenblattAnas YounesHong RenKate HarropNancy WhitingJonathan G. Drachman. (2009) Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 27:26, pages 4371-4377.
Crossref
Crossref
Sukchai Satthaporn, Mark M Aloysius, Richard A Robins, Chandan Verma, Suebwong Chuthapisith, Alasdair J Mckechnie, Mohamad El-Sheemy, Wichai Vassanasiri, David Valerio, David Clark, Jibril A Jibril & Oleg Eremin. (2008) Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. BMC Immunology 9:1.
Crossref
Crossref
Marion Travert, Patricia Ame-Thomas, Céline Pangault, Alexandre Morizot, Olivier Micheau, Gilbert Semana, Thierry Lamy, Thierry Fest, Karin Tarte & Thierry Guillaudeux. (2008) CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-κB Activation and Up-Regulation of c-FLIP and Bcl-xL. The Journal of Immunology 181:2, pages 1001-1011.
Crossref
Crossref
Gunilla Enblad, Daniel Molin, Ingrid Glimelius, Marie Fischer & Gunnar Nilsson. (2007) The Potential Role of Innate Immunity in the Pathogenesis of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America 21:5, pages 805-823.
Crossref
Crossref
Graciana Fuentes-Páez, M Antonia Saornil, José M Herreras, María Alonso-Ballesteros, Pilar Solis Sánchez & Manuel García-Tejeiro. (2007) CHARGE Association, Hyper-Immunoglobulin M Syndrome, and Conjunctival MALT Lymphoma. Cornea 26:7, pages 864-867.
Crossref
Crossref
C. Annette Hollmann, Trevor Owens, Josephine Nalbantoglu, Thomas J. Hudson & Robert Sladek. (2006) Constitutive Activation of Extracellular Signal-Regulated Kinase Predisposes Diffuse Large B-Cell Lymphoma Cell Lines to CD40-Mediated Cell Death. Cancer Research 66:7, pages 3550-3557.
Crossref
Crossref
U. Schönbeck & Peter Libby. 2002. Wiley Encyclopedia of Molecular Medicine. Wiley Encyclopedia of Molecular Medicine.
Khaled A. TolbaWilliam J. BowersShannon P. HilcheyMarc W. HaltermanDarlene F. HowardRita E. GiulianoHoward J. FederoffJoseph D. Rosenblatt. (2001) Development of herpes simplex virus-1 amplicon–based immunotherapy for chronic lymphocytic leukemia. Blood 98:2, pages 287-295.
Crossref
Crossref
Christian Kebelmann-Betzing, Gabriele Körner, Lucia Badiali, Dirk Buchwald, Anja Möricke, Alexander Korte, Joachim Köchling, Shuling Wu, Diane Kappelmeier, Klaus Oettel, Günter Henze & Karlheinz Seeger. (2001) CHARACTERIZATION OF CYTOKINE, GROWTH FACTOR RECEPTOR, COSTIMULATORY AND ADHESION MOLECULE EXPRESSION PATTERNS OF BONE MARROW BLASTS IN RELAPSED CHILDHOOD B CELL PRECURSOR ALL. Cytokine 13:1, pages 39-50.
Crossref
Crossref
Christina M. AnnunziataYassamin J. SafiranSteven G. IrvingUsha N. KasidJeffrey Cossman. (2000) Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor. Blood 96:8, pages 2841-2848.
Crossref
Crossref
Christina M. AnnunziataYassamin J. SafiranSteven G. IrvingUsha N. KasidJeffrey Cossman. (2000) Hodgkin disease: pharmacologic intervention of the CD40-NFκB pathway by a protease inhibitor. Blood 96:8, pages 2841-2848.
Crossref
Crossref
L Li, S.W. Reddel & S.A. Krilis. 2000. Mast Cells and Basophils. Mast Cells and Basophils
97
116
.
Régis T. Costello, Jean-Albert Gastaut & Daniel Olive. (1999) What is the real role of CD40 in cancer immunotherapy?. Immunology Today 20:11, pages 488-493.
Crossref
Crossref
Isabelle Martin, Thierry Bonnefoix, Corinne Roucard, Pascal Perron, Alicia Lajmanovich, Agnès Moine, Dominique Leroux, Jean-Jacques Sotto & Frédéric Garban. (1999) Role of autologous CD4+ T cell clones in human B non-Hodgkin's lymphoma: aborted activation and G1 blockade induced by cell-cell contact. European Journal of Immunology 29:10, pages 3188-3195.
Crossref
Crossref
Aude Charbonnier, Béatrice Gaugler, Danielle Sainty, Marina Lafage-Pochitaloff & Daniel Olive. (1999) Human acute myeloblastic leukemia cells differentiatein vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. European Journal of Immunology 29:8, pages 2567-2578.
Crossref
Crossref
A. YounesA. Carbone. (2018) CD30/CD30 Ligand and CD40/CD40 Ligand in Malignant Lymphoid Disorders. The International Journal of Biological Markers 14:3, pages 135-143.
Crossref
Crossref
Dan JonesChristopher D.M. FletcherKaren PulfordAliakbar ShahsafaeiDavid M. Dorfman. (1999) The T-Cell Activation Markers CD30 and OX40/CD134 Are Expressed in Nonoverlapping Subsets of Peripheral T-Cell Lymphoma. Blood 93:10, pages 3487-3493.
Crossref
Crossref
Patricia Ribeiro, Nathalie Renard, Krzysztof Warzocha, Carole Charlot, Lorena Jeandenant, Evelyne Callet-Bauchu, Bertrand Coiffier & Gilles Salles. (1998) CD40 regulation of death domains containing receptors and their ligands on lymphoma B cells. British Journal of Haematology 103:3, pages 684-689.
Crossref
Crossref
G. Jeanette Thorbecke & Vincent K. TsiagbeV. K. Tsiagbe, N. M. Ponzio, G. S. Erianne, D. J. Zhang, G. J. Thorbecke & G. Inghirami. 1998. The Biology of Germinal Centers in Lymphoid Tissue. The Biology of Germinal Centers in Lymphoid Tissue
199
234
.
H. -J. Gruss. (1996) Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. International Journal of Clinical & Laboratory Research 26:3, pages 143-159.
Crossref
Crossref